Sign in
Taking peoplePhase 3

A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients

Key facts

Who runs it
Hanmi Pharmaceutical Company Limited
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
225 people, planned
Started
Oct 2026
Expected to end
Sept 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HIP2602 + HPP2602-2
  • HPP2602-1 + HPP2602-2
  • HGP1201 + HPP2602-1
Record updated
27 October 2026

Who can take part

Age
19 years to 75 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Visit 1 (screening)
  • Male subjects aged 19 to 75 years, inclusive
  • Subjects with a history of erectile dysfunction for at least 3 months prior to Visit 1
  • Subjects who are expected to have sexual intercourse with the same adult female partner throughout the study period
  • Subjects who agree to attempt sexual intercourse at least 4 times on 4 separate days during the run-in period; Visit 2 (Randomization)
  • Subjects with an International Index of Erectile Function (IIEF) Erectile Function (EF) domain score of ≤25 at Visit 2
  • Subjects who attempted sexual intercourse at least 4 times on 4 separate days during the run-in period and demonstrated a sexual intercourse failure rate of ≥50%, as assessed by the Sexual Encounter Profile (SEP)

Who cannot take part

  • Prior failure to respond to PDE-5 inhibitor therapy
  • Use of prohibited concomitant medications or anticipated need for such medications during the study
  • Participation in another clinical trial within 30 days prior to Visit 1
  • Erectile dysfunction associated with premature ejaculation or endocrine disorders (e.g., hypogonadism, hyperprolactinemia, thyroid disorders)
  • History of radical prostatectomy or other pelvic surgery
  • Presence of anatomical penile deformity (e.g., Peyronie's disease, penile angulation, cavernosal fibrosis)
  • History of major cardiovascular or cerebrovascular disease, including unstable angina, recent myocardial infarction, stroke, uncontrolled arrhythmia, or heart failure
  • History of retinitis pigmentosa, NAION, or other hereditary retinal degenerative disorders
  • Clinically significant hepatic or renal impairment
  • Positive serology for infectious diseases at Visit 1
  • Known hypersensitivity to the study drug or its components
  • Uncontrolled diabetes mellitus (HbA1c > 10% at Visit 1)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 75 years old?

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients

The 3 groups in the trial

  • HIP2602 + HPP2602-2Treatment being tested

    Daily administration, oral

  • HPP2602-1 + HPP2602-2Placebo, for comparison

    Daily administration, oral

  • HGP1201 + HPP2602-1Other group

    Daily administration, oral

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Criteria questions
Built from NCT07899073, who can take part
Record updated
27 October 2026